Never Run Out Of Buyers To Sell To.

Founded in May 2016 near Seoul, South Korea, 1STBIO is focused on developing breakthrough medicines to address the highest unmet needs in oncology and neurology- HPK1 inhibitor (I-O): Phase 1/2 in US - c-Abl inhibitor (neuro): Phase 1 in US and Korea - c-Abl PET tracer for c-Abl patient selection: Entering Phase 1 in EU • Experienced leadership team with a proven business and R&D track record • Small molecule discovery engine that has successfully created highly differentiated drug candidates
Annual Revenue$10M to $25M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.